RxDoctor Payments Data

Barbara Lee, MD

Ophthalmology · Charlotte, NCNPI 1649237124

Payments from drug & device makers

$1,198in general payments, 2019–2025

Across 39 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$421
  • Tarsus Pharmaceuticals, Inc.$270
  • Sun Pharmaceutical Industries Inc.$136
  • AbbVie$114
  • Kala Pharmaceuticals, Inc.$112
  • Bausch & Lomb Americas Inc.$38
  • plus $106 from 4 others

What the payments were for

  • Food & beverage$1,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,198 in reported general payments places this provider in the 40th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$392,643
Medicare patients
1,275
Services billed
2,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$72,026
LumiganBimatoprost92$51,874
Cyclosporine34$20,239
XiidraLifitegrast13$10,202
Brimonidine Tartrate75$8,696
CombiganBrimonidine Tartrate/Timolol17$7,635
Travoprost20$5,308
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$5,104
Latanoprost371$4,625
Timolol Maleate175$2,072
Prednisolone Acetate43$1,734
ValacyclovirValacyclovir Hcl13$798
Tobramycin-DexamethasoneTobramycin/Dexamethasone18$698
Ketorolac Tromethamine27$692
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$114$131,535180 claims
Bausch & Lomb Americas Inc.Xiidra$38$10,20213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →